3 results
The primary objective of this study is to prove noninferiority regarding safety and effectiveness of 30-45 day of DAPT followed by Prasugrel-monotherapy versus standard 12 months of DAPT in patients admitted for STEMI treated by primary PCI.The…
The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab.
The aim of this study is to evaluate the difference in the fraction of patients that have disease progression within 6 months after applying 177Lu-PSMA RLT in patients with low volume, hormone sensitive metastatic prostate cancer. Ultimately, the…